صفحه 1 از جانب 19 نتایج
FIELD OF THE INVENTION
The present invention relates to the use of cannabidiol (CBD) in the treatment of atonic seizures. In one embodiment the patients suffering from atonic seizures are children and young adults. CBD appears particularly effective in reducing atonic seizures in patients suffering
FIELD OF THE INVENTION
The present invention relates to the use of cannabidiol (CBD) in the treatment of atonic seizures. In one embodiment the patients suffering from atonic seizures are children and young adults. CBD appears particularly effective in reducing atonic seizures in patients suffering
FIELD OF THE INVENTION
The present invention relates to the use of cannabidiol (CBD) in the treatment of atonic seizures. In one embodiment the patients suffering from atonic seizures are children and young adults. CBD appears particularly effective in reducing atonic seizures in patients suffering
RELATED APPLICATION
This application claims priority to GB 1418171.3, filed Oct. 14, 2014, which is incorporated herein by reference in its entity.
FIELD OF THE INVENTION
The present invention relates to the use of cannabidiol (CBD) in the treatment of atonic seizures. In one embodiment the patients
FIELD OF THE INVENTION
The present invention relates to the use of cannabidiol (CBD) in the treatment of atonic seizures. In one embodiment the patients suffering from atonic seizures are children and young adults. CBD appears particularly effective in reducing atonic seizures in patients suffering
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to UK 1510664.4, filed Jun. 17, 2015.
FIELD OF THE INVENTION
The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are
The present invention relates to tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives, to pharmaceutical compositions comprising the same and to the use of these tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives in therapy, especially in the treatment of pain.
Pain treatment is often
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage Application under 35 U.S.C. .sctn.371 of International Application No. PCT/US2010/002360, filed Aug. 27, 2010, which claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application Nos. 61/275,506, filed Aug.
FIELD OF THE INVENTION
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB.sub.2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions
RELATED APPLICATION DATA
This application is a National Stage Application under 35 U.S.C. 371 of co-pending PCT application number PCT/EP2013/055728 designating the United States and filed Mar. 19, 2013 and is hereby incorporated herein by reference in its entirety for all purposes.
FIELD OF THE
The present disclosure relates to the fields of pharmaceutical and organic chemistry, and provides 4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB.sub.1 receptor modulators, intermediates for synthesizing these compounds, formulations comprising these compounds, methods for
BACKGROUND OF THE INVENTION
Marijuana (Cannabis sativa L.) and its derivatives have been used for centuries for medicinal and recreational purposes. A major active ingredient in marijuana and hashish has been determined to be .DELTA..sup.9-tetrahydrocannabinol (.DELTA..sup.9-THC). Detailed research
BACKGROUND OF THE INVENTION
Marijuana (Cannabis sativa L.) and its derivatives have been used for centuries for medicinal and recreational purposes. A major active ingredient in marijuana and hashish has been determined to be .DELTA.9-tetrahydrocannabinol (.DELTA.9-THC). Detailed research has
SUMMARY OF THE INVENTION
The present invention is concerned with substituted imidazole of the general Formula I:
##STR00001## and pharmaceutically acceptable salts thereof which are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention
SUMMARY OF THE INVENTION
The present invention is concerned with substituted imidazole of the general Formula I:
##STR00001## and pharmaceutically acceptable salts thereof which are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention